Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Cash from Financing Activities: 2011-2024

Historic Cash from Financing Activities for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to -$34.2 million.

  • Mimedx Group's Cash from Financing Activities fell 3274.07% to -$857,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year increase of 87.77%. This contributed to the annual value of -$34.2 million for FY2024, which is 299.05% down from last year.
  • Mimedx Group's Cash from Financing Activities amounted to -$34.2 million in FY2024, which was down 299.05% from -$8.6 million recorded in FY2023.
  • Over the past 5 years, Mimedx Group's Cash from Financing Activities peaked at $61.6 million during FY2020, and registered a low of -$34.2 million during FY2024.
  • For the 3-year period, Mimedx Group's Cash from Financing Activities averaged around -$14.4 million, with its median value being -$8.6 million (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 82.70% in 2022, then plummeted by 1,377.59% in 2023.
  • Mimedx Group's Cash from Financing Activities (Yearly) stood at $61.6 million in 2020, then tumbled by 105.45% to -$3.4 million in 2021, then soared by 82.70% to -$580,000 in 2022, then plummeted by 1,377.59% to -$8.6 million in 2023, then tumbled by 299.05% to -$34.2 million in 2024.